JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Registered Office:Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Hyderabad-500008. CONSOLIDATED UN AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2019

Rupees in Lakhs Previous Year **Ouarter Ended** Ended **Particulars** SI.No 31-03-2019 30-06-2019 31-03-2019 30-06-2018 Un Audited Audited Un Audited Audited 1 Income 434.21 606.90 2,612.77 317.31 (a) Revenue From Operations 7.20 23.97 97.14 25.56 (b) Other Income 2,709.91 342.87 441.41 630.87 Total income Expenses 37.78 25.42 36.90 164.18 (a) Cost of Material Consumed (b) Purchase of stock-in-trade (c) Changes in Inventories of finished goods, work-in-progress and stock-in-trade 197.73 178.95 835.56 217.06 (d) Employee benefit expense 34.34 42.85 190.08 (e) Finance Cost 61.01 313.16 98.59 70.40 65.67 (f) Depreciation and Amortisation expense 1,070.38 (g) Other Expenses 196.03 276.32 257.75 2,573.36 582.12 610.47 604.21 **Total Expenses** 136.55 Profit before exceptional items and Tax -267.60 -162.80 48.75 4 Add(+)/Less(-) Exceptional items -267.60 -162.80 48.75 136.55 Profit before Tax 57.51 -13.40 10.14 25.15 6 Tax Expenses -210.09 -149.40 38.61 111.40 7 Profit(Loss) for the Period from Continuing Operations Profit(Loss) from Discontinuing Operations _ -9 Tax Expenses on discontinuing Operations



	Particulars	Quarter Ended			Year Ended
Sl.No		30-06-2019	31-03-2019	30-06-2018	31-03-2019 Audited
		Un Audited	Audited	Un Audited	
10	Profit(Loss) from Discontinuing Operations after Tax	-		-	
1					
11	Profit(Loss) for the period	-210.09	-149.40	38.61	111.40
12	Other Comprehensive Income				
	A (i) Items that will not be reclassfied to profit or loss	0.34	1.19	0.89	1.94
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	(0.33)	-	(0.54)
	B (i) Items that will be reclassified to profit or loss		-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss		-	-	-
	N				
13	Total Comprehensive Income for the period	-209.75	-148.54	39.50	112.80
14	Paid Up Equity Share Capital (Face Value of Rs.10/- each)	1,530.15	1,530.15	1,530.15	1,530.15
15	Other equity excluding revaluation reserve				1,653.17
16	Earnings per Equity share (for continuing operations)				
	a) Basic (Amount in Rupees)	-1.37	-0.97	0.26	0.74
	b) Diluted (Amount in Rupees)	-1.37	-0.97	0.39	0.78
17	Earnings per Equity share (for discontinued operations)				
	a) Basic (Amount in Rupees)		-	-	-
	b) Diluted (Amount in Rupees)		-	-	
18	Earnings per Equity share (for Continuing & discontinued operations)				^ - 4
	a) Basic (Amount in Rupees)	-1.37	-0.97	0.26	0.74
	b) Diluted (Amount in Rupees)	-1.37	-0.97	0.39	0.78

Notes to the Consolidated Un Audited Financial Results

- 1 The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015
- The above results have been reviewed by the Audit Committee at its meeting held on 13.08.2019 and approved by the Board of Directors of the Company at its meeting held on 13.08.2019. These Results are also subjected to Limited Review by the Company's Statutory Auditors.
- 3 The Figures for the Quarter Ended 31-03-2019 are the balancing figures between the audited figures for the full financial year and the published year to date figures up to the 3rd Quarter of the respective financial year.
- 4 The Group currently has two segments (i) clinical research services and (ii) Information technology services.
- The Group has adopted Ind As-116, effective annual reporting period beginning April 1, 2019 and applied the standard to its leases. However, there is no impact on the financials of the company.
- 6 Figures for the previous periods have been rearranged whereever necessary.
- 7 The above consolidated financial results include the Un Audited financial results of the wholly owned subsidiaries, M/s Enhops Solutions Pvt Ltd & Enhops Inc.

Place:Hyderabad Date:13.08.2019



SEGMENT-WISE REVENUE, RESULTS & CAPITAL EMPLOYED (Consolidated Unaudited) UNDER CLAUSE 41 OF THE LISTING AGREEMENT FOR THE QUARTER ENDED 30TH JUNE, 2019

Particulars	Quarter Ended			Year Ended	
	30-06-2019	31-03-2019	30-06-2018	31-03-2019	
	Un Audited	Audited	Un Audited	Audited	
SEGMENT REVENUE: (Net Sales / Income from Operations)					
a) Clinical Research Services	316.38	427.61	585.83	2,636.	
b) Information Technology Services	26.49	13.80	21.07	73.	
c) Data Management Services	-	-		-	
d) Unallocable income	_	-	23.97		
Total:	342.87	441.41	630.87	2,709	
LESS: Inter Segment revenue		-	-	-	
Net Sales/income from Operations.	342.87	441.41	630.87	2,709	
SEGMENT RESULTS : PROFIT / (LOSS) BEFORE TAX AND INTEREST					
a) Clinical Research Services	-203.81	-120.22	67.61	333	
b) Information Technology Services	-2.78	-6.97	0.02	-5	
c) Data Management Services	-	-	-	-	
Total:	-206.59	-127.19	67.63	327	
LESS:					
i) Interest	61.01	34.34	42.85	190	
ii) Other Un-Allocable Expenditure	-	1.27	-	1	
iii) Un-Allocable Income	-	-	-23.97		
TOTAL PROFIT /(-LOSS) BEFORE TAX	-267.60	-162.80	48.75	13	

Place:Hyderabad Date: 13.08.2019 for Jeevan Scientific Technology Limited On behalf of the Board of Directors

K. Krishna Kishore

Vice Chairman & Managing Director